Tunlametinib not checked

Shanghai Kechow Pharma, Inc. · HL-085

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 3 trial completes
Trials
3 active
10 in total
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
How it’s given
“IIa: HL-085 capsule 9mg administered orally twice daily in a continuous 21-day treatment cycle. If required, dosing schedule can be adjusted to 12mg BID, 6mg BID, or other dosage regimens. IIb: HL-085 at the recommended dose or dosage regimen.”In the company’s words, NCT05331105 on ClinicalTrials.gov
Tested for
Colorectal Cancer Metastatic, Melanoma, Neurofibromatosis 1, Plexiform Neurofibromas
Main trialPhase 3
“This is a multicenter, randomized, open-label, Phase 3 study”In the company’s words, NCT06008119 on ClinicalTrials.gov
Other names
HL-085

Other drugs for Colorectal Cancer Metastatic

All 392 drugs for Colorectal Cancer Metastatic

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 24 Dec 2026 Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Phase 3Recruiting 22 Sep 2027 Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Phase 2Recruiting 30 Oct 2025 HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Phase 2Completed 19 Feb 2023 HL-085 in NRAS-mutated Advanced Melanoma
Phase 2Unknown 20 Jan 2024 Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
Phase 2Unknown 30 Sep 2024 HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Phase 1/2Completed 18 Jan 2021 Study of HL-085 in NRAS Mutant Advanced Melanoma
Phase 1Terminated 20 Jul 2021 Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
Phase 1Completed 15 Sep 2022 Study of HL-085 in Patients With Advanced Solid Tumor Tumors
Phase 1Unknown 1 Dec 2023 A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tunlametinib

Following is part of Solo: you see every change to Tunlametinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in